Pfizer Inc.
CDK2/4/6 inhibitors

Abstract:

This invention relates to compounds of general Formula (I) ##STR00001## and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.2A, R.sup.2B, R.sup.3, R.sup.4, R.sup.5A, R.sup.5B, R.sup.6, R.sup.7, R.sup.8, R.sup.9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.